U.S. Markets open in 7 hrs, 34 mins
| Symbol | Value | Change | Percentage Change |
|---|---|---|---|
| DJIA | 11,632.38 | 29.88 | 0.26% |
| NASDAQ | 2,325.88 | 21.92 | 0.95% |
| S&P 500 | 1,282.19 | 5.19 | 0.41% |
| Day Low 09:30 AM EDT | 51.26 | |
|---|---|---|
| Day High 11:14 AM EDT | 53.45 |
|
| Range | 2.19 | |
| Volume | 12.92 M | |
| 30-Day Avg. Vol. | 9.53 M |
|
| Difference | 35.61% | |
| Market Cap. | 48.61 B | |
| Change | 1.47 B | |
| Shares Out. | 922.46 M | |
| Percent Traded | 1.40% | |
| Revenue | 4.23 B | |
| Earnings | 1.61 B | |
| EPS (TTM) | 1.80 |
| 52-Wk Low 8/29/07 | 35.22 | |
|---|---|---|
| 52-Wk High 6/5/08 | 56.95 |
|
| Range | 21.73 | |
| Prev. Close 7/22/08 | 51.10 | |
| Today's Open | 51.43 | |
| Change | 0.65% | |
| Dividend (TTM) | 0.00 | |
| Div. Yield (TTM) | 0.00% |
|
| Beta | 0.5285 | |
| P/E Ratio (TTM) | 29.44 | |
| P/E Ratio (Fwd.) | 25.00 |
Gilead Sciences has biotech balms for infectious diseases, including hepatitis, HIV, and infections related to AIDS. The company's HIV franchise includes blockbuster Truvada, a combination of two of its ... View Full Description
| Earnings/Share(EPS) | Estimate | Actual | Difference |
|---|---|---|---|
| 2 Quarters Ago | 0.479 3/31/08 | 0.51 3/31/08 |
0.031
Beat
|
| Last Quarter | 0.48 6/30/08 | 0.46 6/30/08 |
-0.02
Missed
|
| Quarterly - 06/30/2008 | Annual - 2007 | |
|---|---|---|
| Total Revenue | 1.28 B | 4.23 B |
| Gross Profit | 1.01 B | 3.46 B |
| Operating Income | 605.52 M | 2.16 B |
| Net Income | 442.83 M | 1.62 B |
Real-Time Quote
